Market Cap | 37.05M | P/E | - | EPS this Y | 29.00% | Ern Qtrly Grth | - |
Income | -27.41M | Forward P/E | -1.81 | EPS next Y | 20.40% | 50D Avg Chg | -10.00% |
Sales | 958.03k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
Dividend | N/A | Price/Book | 1.33 | EPS next 5Y | - | 52W High Chg | -73.00% |
Recommedations | 2.50 | Quick Ratio | 3.25 | Shares Outstanding | 27.42M | 52W Low Chg | 50.00% |
Insider Own | 24.68% | ROA | -55.84% | Shares Float | 19.61M | Beta | 0.02 |
Inst Own | 22.04% | ROE | -113.54% | Shares Shorted/Prior | 11.66K/93.20K | Price | 1.36 |
Gross Margin | 47.81% | Profit Margin | - | Avg. Volume | 56,337 | Target Price | 3.13 |
Oper. Margin | -59,369.08% | Earnings Date | Mar 29 | Volume | 8,201 | Change | -3.55% |
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
Piper Sandler | Overweight | May 12, 23 |
Piper Sandler | Overweight | Apr 3, 23 |
Piper Sandler | Overweight | Nov 15, 22 |
Piper Sandler | Overweight | Aug 31, 22 |
Craig-Hallum | Buy | Jul 19, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Douglas James Michael | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 51,250 | 03/30/23 |
Ross Jeffrey James | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 396,276 | 03/30/23 |
Barry John Joseph | VICE PRESIDENT OF R&.. VICE PRESIDENT OF R&D | Mar 10 | Buy | 1.60 | 6,250 | 10,000 | 35,485 | 03/30/23 |
BUCKMAN PAUL | Director Director | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 52,593 | 03/30/23 |
Maag Peter | Director Director | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 66,259 | 03/30/23 |
ERB JOHN L | Director Director | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 56,260 | 03/30/23 |
Burke William P. Mr. | Director Director | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 80,155 | 03/30/23 |
Heine Lisa Wipperman | Director Director | Mar 10 | Buy | 1.60 | 31,250 | 50,000 | 80,155 | 03/30/23 |
Ross Jeffrey James | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Dec 06 | Option | 1.25 | 37,500 | 46,875 | 331,088 | 12/08/22 |
Ross Jeffrey James | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Mar 15 | Option | 1.25 | 35,438 | 44,298 | 293,588 | 03/17/22 |